Abstract
Patients with carotid atherosclerotic plaques, adding ginsenoside Rg1 to standard therapy reduced the number and volume of carotid plaques. It improved quality of life, decreased specific inflammatory markers, and enhanced blood pressure control and Insulin Resistance (IR). These suggest ginsenoside Rg1 may have clinical value in the future management of carotid atherosclerosis.
Introduction
Carotid atherosclerosis—the accumulation of fatty plaques in the primary arteries of the neck—represents a significant risk factor for ischemic strokes and cardiovascular events. While current standard-of-care treatments involving statins and aspirin are effective at slowing disease progression, they are not without limitations. Long-term aspirin use carries risks of gastrointestinal bleeding, and many patients continue to experience plaque growth despite adherence to therapy.
There is an urgent clinical need for sustainable therapeutic alternatives that not only stop plaque growth but actively promote regression while minimizing side effects. Researchers investigated whether ginsenoside Rg1, a primary active component of the Panax notoginseng (Sanqi) plant, could address this gap. Known for its anticoagulant and anti-inflammatory properties in Traditional Chinese Medicine (TCM), Rg1 was tested for its ability to match or exceed the efficacy of standard antiplatelet regimens in plaque management.
Methods
The researchers conducted a single-blind, randomized controlled trial involving 106 patients (aged 60–74) with confirmed carotid plaques. Participants were recruited from the Geriatrics Department of the First People’s Hospital of Yunnan Province, China.
As shown in the study design above, participants were divided into three groups to evaluate a "replacement" strategy:
- Group 1 (Control): Lifestyle interventions + Atorvastatin (a statin).
- Group 2 (Standard Care): Lifestyle + Atorvastatin + Bayaspirin (aspirin).
- Group 3 (Experimental): Lifestyle + Atorvastatin + Ginsenoside Rg1 (QiShengli Tablets, 15mg Rg1 per tablet).
The study lasted three months. Baseline characteristics such as age, gender, and smoking history were statistically balanced across all three groups to ensure the validity of the results.
Key Results and Insights
Active Plaque Regression
Unlike many studies that only demonstrate a slowing of plaque growth, this trial observed a statistically significant reduction in both the number and volume of plaques in the Rg1 group. Group 3 (Rg1) saw a dramatic drop in plaque volume from a median of 44.280 to 31.960 ($P < 0.005$). In contrast, the control group saw no statistically significant change.
Multimodal Biological Action
Rg1 appeared to act as a "poly-pill," simultaneously targeting several pathological pathways:
- Inflammation: Significant post-treatment reductions were noted in IL-6 and TNF-α for the Rg1 group, indicating a potent systemic anti-inflammatory effect.
- Lipids & Metabolism: Rg1 treatment led to superior reductions in LDL-C, Total Cholesterol (TC), and Homocysteine (Hcy) compared to the aspirin and control groups. It also appeared to decrease insulin resistance (IR).
- Vascular Health: Pulse Wave Velocity (PWV), a measure of arterial stiffness, improved significantly in the Rg1 group ($P < 0.05$). The study also highlighted Fibroblast Growth Factor 21 (FGF21) as a key marker, suggesting the compound may help combat vascular senescence (the aging of blood vessels).
Cognitive Synergy
Interestingly, patients in the Rg1 group showed improved scores on the Montreal Cognitive Assessment (MoCA). This suggests that improving carotid health and reducing systemic inflammation may have secondary benefits for brain health and cognitive function in elderly populations.
Limitations and Future Work
While the results are promising, several factors limit the immediate broad application of these findings:
- Sample Size: With 106 participants, the study is relatively small. Larger, multi-center trials are required to generalize these results.
- Duration: A 3-month follow-up is short for a chronic condition like atherosclerosis. Long-term studies are needed to confirm if these plaque reductions translate into a lower incidence of actual strokes or heart attacks.
- Study Design: The single-blind nature of the study introduces a higher risk of bias than a double-blind, placebo-controlled trial.
Conclusion
Ginsenoside Rg1 shows significant potential as an adjunctive therapy for carotid atherosclerosis, offering a multi-targeted approach that addresses lipids, inflammation, and vascular aging simultaneously. It may eventually serve as a viable alternative or supplement to traditional antiplatelet therapies for patients at risk of cardiovascular events.
Summary updated